Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients

German study reported DOACs account for 45% of anticoagulant use in adult congenital heart disease in 2018 but associated with increased risk of MACE (HR 1.22), all-cause mortality (1.43; both P < 0.001) and bleeding (1.16; P = 0.007) vs VKAs during long-term follow-up.

European Heart Journal